Abstract:Luteolin is a natural flavone with neurotrophic effects observed on different neuronal cell lines. In the present study, we aimed to assess the effect of luteolin on hNSCs fate determination and the LPS-induced neuroinflammation in a mouse model of depression with astrocytogenesis defect. hNSCs were cultured in basal cell culture medium (control) or medium supplemented with luteolin or AICAR, a known inducer of astrogenesis. A whole-genome transcriptomic analysis showed that luteolin upregulated the expressions of genes related to neurotrophin, dopaminergic, hippo, and Wnt signaling pathways, and downregulated the genes involved in p53, TNF, FOXO, and Notch signaling pathways. We also found that astrocyte-specific gene GFAP, as well as other genes of the key signaling pathways involved in astrogenesis such as Wnt, BMP, and JAK-STAT pathways were upregulated in luteolin-treated hNSCs. On the other hand, neurogenesis and oligodendrogenesis-related genes, TUBB3, NEUROD 1 and 6, and MBP, were downregulated in luteolin-treated hNSCs. Furthermore, immunostaining showed that percentages of GFAP+ cells were significantly higher in luteolin- and AICAR-treated hNSCs compared to control hNSCs. Additionally, RT-qPCR results showed that luteolin upregulated the expressions of GFAP, BMP2, and STAT3, whereas the expression of TUBB3 remained unchanged. Next, we evaluated the effects of luteolin in LPS-induced mice model of depression that represents defects in astrocytogenesis. We found that oral administration of luteolin (10 mg/Kg) for eight consecutive days could decrease the immobility time on tail suspension test, a mouse behavioral test measuring depression-like behavior, and attenuate LPS-induced inflammatory responses by significantly decreasing IL-6 production in mice brain-derived astrocytes and serum, and TNFα and corticosterone levels in serum. Luteolin treatment also significantly increased mature BDNF, dopamine, and noradrenaline levels in the hypothalamus of LPS-induced depression mice. Though the behavioral effects of luteolin did not reach statistical significance, global gene expression analyses of mice hippocampus and brain-derived NSCs highlighted the modulatory effects of luteolin on different signaling pathways involved in the pathophysiology of depression. Altogether, our findings suggest an astrocytogenic potential of luteolin and its possible therapeutic benefits in neuroinflammatory and neurodegenerative diseases. However, further studies are required to identify the specific mechanism of action of luteolin.

Luteolin Mitigates Dopaminergic Neuron Degeneration and Restrains Microglial M1 Polarization by Inhibiting Toll Like Receptor 4

Luteolin Inhibits SH-SY5Y Cell Apoptosis Through Suppression of the Nuclear Transcription Factor-Κb, Mitogen-Activated Protein Kinase and Protein Kinase B Pathways in Lipopolysaccharide-Stimulated Cocultured BV2 Cells.

Luteolin reduces primary hippocampal neurons death induced by neuroinflammation.

Luteolin Inhibits Microglial Inflammation and Improves Neuron Survival Against Inflammation

Luteolin Suppresses Microglia Neuroinflammatory Responses and Relieves Inflammation-Induced Cognitive Impairments

Luteolin protects microglia against rotenone-induced toxicity in a hormetic manner through targeting oxidative stress response, genes associated with Parkinson’s disease and inflammatory pathways

TLR4 deficiency has a protective effect in the MPTP/probenecid mouse model of Parkinson’s disease

Regulation of Ubiquitin-Specific Processing Protease 8 Suppresses Neuroinflammation

Exploring the mechanism of luteolin by regulating microglia polarization based on network pharmacology and in vitro experiments

Dihydromyricetin attenuates inflammation through TLR4/NF-kappaB pathway

Lutein suppresses inflammatory responses through Nrf2 activation and NF‐κB inactivation in lipopolysaccharide‐stimulated BV‐2 microglia

The Inhibitory Effect of Luteolin on Inflammation in LPS-induced Microglia

Luteolin alleviates cognitive impairment in Alzheimer’s disease mouse model via inhibiting endoplasmic reticulum stress-dependent neuroinflammation

Luteolin ameliorates chronic stress-induced depressive-like behaviors in mice by promoting the Arginase-1 + microglial phenotype via a PPARγ-dependent mechanism

Polydatin Prevents Lipopolysaccharide (LPS)-Induced Parkinson's Disease via Regulation of the AKT/GSK3β-Nrf2/NF-κB Signaling Axis

Effect of luteolin on the behavior of levodopa induced dyskinesia rat model and the possible mechanisms

Luteolin Modulates Neural Stem Cells Fate Determination: In vitro Study on Human Neural Stem Cells, and in vivo Study on LPS-Induced Depression Mice Model

Paeoniflorin Alleviates Neuroinflammatory Response by Suppressing HMGB1/RAGE Pathway Activation in MPTP Induced Mouse PD Model

Tubeimoside I Protects Dopaminergic Neurons Against Inflammation-Mediated Damage in Lipopolysaccharide (Lps)-Evoked Model of Parkinson’s Disease in Rats

Protective Effects of Luteolin Against Amyloid Beta-Induced Oxidative Stress and Mitochondrial Impairments Through Peroxisome Proliferator-Activated Receptor Γ-Dependent Mechanism in Alzheimer's Disease.

Tubeimoside I Protects Dopaminergic Neurons Against Inflammation-Mediated Damage in Lipopolysaccharide (LPS)-Evoked Model of Parkinson's Disease in Rats